Inmune Bio, Inc. (INMB) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.23

From 52W high−7.17%

Volume675403.00

Market cap$64.67M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$2.23

From 52W high

−7.17%

Volume

675403.00

Market cap

$64.67M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

P/E (TTM)

—

RSI (14)

51.3

MomentumView details →

1D Return

+6.88%

YTD Return

+44.23%

SummaryUpdated Jun 1, 2026

INmune Bio, Inc. (NASDAQ:INMB) is a clinical-stage immunotherapy company founded in 2015 and headquartered in Boca Raton, Florida. The company went public in February 2019 and focuses on developing innovative treatments that reprogram the patient's innate immune system to combat disease. INmune Bio operates three distinct therapeutic platforms targeting neuroinflammation in Alzheimer's disease, oncology applications through novel NK cell therapy, and rare diseases affecting skin integrity.

Ask drillr about Inmune Bio, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−90.44%

ROA (TTM)

−68.60%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+72.29%

FCF YoY

—

Revenue CAGR 3Y

−48.87%

EPS CAGR 3Y

+11.85%

EBITDA YoY

+53.44%

MomentumView details →

1D Return

+6.88%

YTD Return

+44.23%

1Y Return

+18.42%

RSI (14)

51.3

vs 50D SMA

+7.27%

vs 200D SMA

+37.72%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

4.04x

Quick Ratio

4.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.05

EPS Surprise

75.81%

Beats (12Q)

7/12

Next Q EPS Est

−$0.15

Avg Surprise (4Q)

36.88%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−18.42M

Op. CF (TTM)

−14.97M

Next earningsOct 29, 2026 →

Latest newsMore news →

INmune Bio Inc. appointed R. Duane Clark II and James Sapirstein as directors, effective September 8, 2026, each receiving an option to purchase 100,000 shares.6d ago

INmune Bio submitted an Orphan Drug Designation application and a pre-MAA Scientific Advice package to the European Medicines Agency for Ebstrocel in recessive dystrophic epidermolysis bullosa, supporting a planned EU marketing authorization application in Q1 2027.25d ago

Similar companies

MindWalk Holdings Corp.HYFT Boundless Bio, Inc.BOLD Cassava Sciences, Inc.SAVA Gossamer Bio, Inc.GOSS Spero Therapeutics, Inc.SPRO Alps Group IncALPS Find similar companies →

Latest newsMore news →

INmune Bio Inc. appointed R. Duane Clark II and James Sapirstein as directors, effective September 8, 2026, each receiving an option to purchase 100,000 shares.6d ago INmune Bio submitted an Orphan Drug Designation application and a pre-MAA Scientific Advice package to the European Medicines Agency for Ebstrocel in recessive dystrophic epidermolysis bullosa, supporting a planned EU marketing authorization application in Q1 2027.25d ago